PMH7: CROSS-CULTURAL ADAPTATION OF THE INTERNATIONAL INDEX OF ERECTILE FUNCTION (IIEF) IN 31 COUNTRIES  by Conway, K et al.
Abstracts 33
in 9 of the 11 countries studied, and for inpatients in 10
of the 11 countries studied. The weighted average ex-
pected cost per patient for MDD treatment varied from
US $642 (Poland) to US $5,825 (US). The estimated bud-
getary impact to the primary payer for each 1% of utili-
zation of extended-release venlafaxine ranged from US
$61,640 (Switzerland) to US $1,565,900 (Germany) for
each 1 million population. 
CONCLUSIONS: Policy-makers should implement mea-
sures to increase the utilization of cost-effective antide-
pressant treatment such as extended-release venlafaxine.
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Thwaites RMA1, Yeardley HL2
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OBJECTIVE: To assess the relationship between illness
severity and costs of care in noninstitutionalized patients
with Alzheimer’s Disease in the United Kingdom.
METHODS: In this cross-sectional, multicenter analysis,
Alzheimer’s Disease patients cared for in the community
(128), their caregivers (128), and 56 matched controls
were recruited chronologically and interviewed once to
establish resource use over the previous 3 months. Pa-
tients were stratified into three severity groups according
to their cognitive function as assessed by their Mini Men-
tal State Exam score. Costs were calculated from the per-
spective of society as a whole.
RESULTS: Over the 3-month period, total mean cost per
control subject (£387) was minor compared with the
mean cost incurred by patients with mild (£6,616), mod-
erate (£10,250), and severe (£13,593) Alzheimer’s Dis-
ease. Indirect cost, mainly time spent by caregivers, was
the main cost component in all groups (68.6%), followed
by direct medical costs (24.7%).
CONCLUSION: The cost of care for an Alzheimer’s Dis-
ease patient is substantial and is directly related to the se-
verity of the patient’s illness.
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OBJECTIVE: To develop a health-related quality of life
questionnaire to measure the effects of treatment on the
quality of life of people with schizophrenia, the Schizo-
phrenia Quality of Life Scale (SQLS).
METHODS: A standardized state-of-the-art methodol-
ogy has been used for the development of the SQLS.
Items were generated from in-depth interviews with 20
patients and eight health professionals. From a list of 440
statements, a pilot questionnaire containing 80 items was
developed by a panel of experts. The pilot questionnaire
was tested on 20 patients, which resulted in some word-
ing changes. A sample of 161 patients completed the 80-
item questionnaire. A factor analysis using Varimax rota-
tion was then conducted. This identified 31 questions
tapping three factors: psychological, motivational, and
physical symptoms. The psychometric properties of the
SQLS were then assessed using the following methodol-
ogy. Sixty-five patients were given the SQLS to complete,
along with the following measures: the SF-36, the Hospi-
tal Anxiety and Depression Scale (HADS), and the Gen-
eral Health Questionnaire (GHQ-12). A clinical assess-
ment using the Clinical Global Impressions and the
Health of the Nation Outcome Scales (HONOS) was
made by a psychiatrist. A subset of the patients was asked
to complete the SQLS for a second time to assess the re-
producibility of the measure.
RESULTS: The validity and reliability of the scale are
good. 
CONCLUSIONS: The SQLS is now available for use, al-
though further studies of its psychometric properties are
ongoing.
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With the increase of QoL assessment in clinical trials, it is
necessary to have cross-culturally valid instruments to
make comparisons of health status outcomes and pool
data across countries. The IIEF is a 15-item instrument
designed in English to assess erectile dysfunction. Prior to
use in an international trial, it underwent cross-cultural
adaptation in 31 languages. This involved the recruitment
of a QoL specialist in each target country. Two indepen-
dent forward translations were produced by native speak-
ers, bilingual in English. These were reconciled and back-
translated into English. The translations were tested for
comprehension in a sample target population, compared
and internationally harmonized. The developer clarified
concepts underlying each item. Translation was difficult,
especially when selecting equivalent response categories
and appropriate equivalents of common English struc-
tures and expressions. The difficulty of the translation
and its acceptability depended on the comparability of
the original and the target language and culture. Because
English is flexible, it was possible to accept “Most of the
times (much more than half of the time)” as an answer to
the question: “How often have you felt sexual desire in
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the last 4 weeks?” In many languages a literal translation
would have been unclear and so the question was re-
placed by “how much of the time. . . .” Patient testing
showed different reactions to the instrument across coun-
tries and made it clear that terms such as “intercourse,”
“erection,” or “ejaculation” were not always understood
and required explanation. Prior to use in an international
trial, rigorous cultural adaptation was essential to pro-
duce cross-culturally valid language versions. Psychomet-
ric testing will be important to ensure similar relation-
ships among scales across countries. The comparison of
answer patterns across countries will clarify whether peo-
ple with similar health give equivalent answers.
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OBJECTIVE: To evaluate the economic effect of using
risperidone in nursing home residents with documented
behavioral and psychological signs and symptoms of de-
mentia (BPSSD).
METHODS: Based on 1995 data from a large nursing
home database, the average annual incremental cost of
care due to BPSSD was calculated for three diagnosis
groups (All Diagnoses, All Dementia, and Non-Demen-
tia). These costs, in 1997 US dollars, included increased
reimbursement resulting from transition to a higher level
of care and more frequent physician visits due to BPSSD.
These were compared with the cost of 1 mg per day ris-
peridone therapy.
RESULTS: BPSSD was documented in 13.5% of all nurs-
ing home residents—in 20% of those with dementia and
in 11% in those without dementia. The annual cost of
risperidone was estimated at $101, $148, and $85, re-
spectively, per patient in each group. The BD-related
costs considering all patients, regardless of behavioral
status, were $245, $383, and $195, respectively, per resi-
dent in each group. Risperidone was estimated to break
even if 42% of BPSSD-related transitions to a higher level
of care were prevented among all patients, 39% if only
demented patients are considered, and 44% for those
without dementia. With higher effectiveness, treatment
with risperidone would result in cost-savings. 
CONCLUSIONS: The use of risperidone in institutional-
ized patients with BPSSD should provide not only sub-
stantial relief of what can be a difficult-to-manage situa-
tion but also a favorable economic effect.
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OBJECTIVES: The annual prevalence and annual inci-
dence of the diagnosis of multiple sclerosis (MS) in the UK
were determined, together with the therapies employed,
the associated costs, and the referrals to secondary care.
METHODS: This study used UKPCD, which contains
longitudinal records of nearly 2 million patients. Data are
captured daily from general practitioners who use the
AAH Meditel System 5 software as part of their standard
record keeping. Patients were selected according to the
primary care coding system, “Read,” (entered as a prob-
lem or problem-linked note code), from June 1997 to
June 1998. Therapies, prescription costs, and referrals
were extracted from these patients’ records.
RESULTS: The annual prevalence of MS was 62/100,000
(95% CI 58–66); the annual incidence was 7/100,000
(95% CI 6–8). A comparison of all therapies used to
manage MS patients showed apparent differences between
prevalent and incident patients, except in antidepressants
(36% both groups). Non-narcotic analgesics were pre-
scribed for 45% of prevalent patients and 32% of incident
patients. When therapy for prevalent patients was linked
to the Read code for MS, 33% of patients were prescribed
central muscle relaxants and 24% antidepressants. The
cost to the community for all prescribed products in the
study year was £159,508. The majority of note referrals
for both prevalent and incident patients was for neurolo-
gist care (20% and 40%) and physiotherapy (12% and
14%), respectively.
CONCLUSION: This study is an example of the use of an
automated, observational, primary care database such as
MediPlus in pharmacoeconomic and outcomes research.
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OBJECTIVE: Patients report in general to be dissatisfied
with headache treatment. A disease management pro-
gram was developed to improve the quality of headache
treatment of a general sick fund–insured population.
METHOD: Employees at a ship-building site (n  1996)
and their families were asked to fill in questionnaires if
they suffered from headache: the Short-Form 36, the Kiel
